Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.711 -0.069 (-3.90%)
Streaming Delayed Price Updated: 11:45 AM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about OS Therapies Incorporated Common Stock

Which stocks are gapping on Monday?
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
OS Therapies advances OST-HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma. 
Via Benzinga
Friday's session: gap up and gap down stocks
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024
OS Therapies just reported results for the second quarter of 2024. 
Via InvestorPlace
Top movers in Friday's pre-market session
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why
Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves. 
Via Stocktwits
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector 
Via News Direct
Transforming Oncology: Stocks to Watch in the Oncology Sector
Transforming Oncology: Stocks to Watch in the Oncology Sector 
Via News Direct
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
OS Therapies Falls Following Downsized IPO
Shares of OS Therapies fell on Thursday following a downsized initial public offering by the oncology drug developer in a slow week for the IPO market. 
Via Talk Markets
Topics Initial Public Offering
Dow Dips Over 400 Points; Apple Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.